US 2022/0010004 A1 · PROTEIN-BASED THERAPY AND DIAGNOSIS OF TAU-MEDIATED PATHOLOGY IN ALZHEIMER'S DISEASE

Abstract

The invention provides unique therapeutic and diagnostic antibodies, as well as their fragments, portions, derivatives, and variants thereof, that bind regions of the tau protein that contribute to the initiation and propagation of pathological tau-tau interactions, as well as methods of making them. The invention also relates to methods of using those antibodies for diagnostics, prevention, and treatment of Alzheimer's disease and related tauopathies. The present invention also provides a method for a prophylactic and therapeutic treatment of Alzheimer's disease and other neurodegenerative tauopathies. This method entails the injection of antibodies and/or pep tide vaccines that elicits an immune response directed to pathological tau proteins and tau deposits in the brains of patients. Suitable vaccines represent a tau peptide carrying one or more of the tau therapeutic epitopes provided herein.

Claims25

Dependent claims

1-116. (canceled)

An anti-tau antibody or antigen-binding fragment thereof that binds to one or more tau epitopes, wherein the antibody or antigen-binding fragment comprises:

a) a light chain variable region comprising:
i. a CDR1 comprising SEQ ID NO:
117 or SEQ ID NO:
248;
ii. a CDR2 comprising SEQ ID NO:
118 or SEQ ID NO:
253;
and
iii. a CDR3 comprising SEQ ID NO:
119, SEQ ID NO:
254, SEQ ID NO:
255, SEQ ID NO:
257, SEQ ID NO:
258, SEQ ID NO:
259, or SEQ ID NO:
260;
and
b) a heavy chain variable region comprising:
i. a CDR1 comprising SEQ ID NO:
120, SEQ ID NO:
261, or SEQ ID NO:
262;
ii. a CDR2 comprising SEQ ID NO:
121, SEQ ID NO:
264, or SEQ ID NO:
265;
and
iii. a CDR3 comprising SEQ ID NO:
122, SEQ ID NO:
266, SEQ ID NO:
267, or SEQ ID NO:
269;
wherein the antibody or antigen-binding fragment does not comprise the CDR combination of SEQ ID NO:
117, SEQ ID NO:
118, SEQ ID NO:
119, SEQ ID NO:
120, SEQ ID NO:
121, and SEQ ID NO:
122.

36 more elements

Dependencies are inferred from the claim text.

Facts

Application

17/443,779Filed 27 Jul 2021

Priority

19 Sep 2011

Published

13 Jan 2022

Term ends

Not estimatedThe source records don’t support an estimate.

Classification33 codes

C07K 16/18
Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies: against material from animals or humans
A61K 38/1709
From vertebrates: from mammals
A61K 39/0007
Vertebrate antigens: nervous system antigens; Prions
A61K 39/3955
Against materials from animals: against proteinaceous materials, e.g. enzymes, hormones, lymphokines

Family

Application61/536,339Us provisional application · filed 19 Sep 2011

Application61/653,115Us provisional application · filed 30 May 2012

Application14/345,561Division · filed 5 Nov 2014

Application15/342,629Continuation · filed 3 Nov 2016

Application15/599,685Division · filed 19 May 2017

Application15/801,341Continuation · filed 2 Nov 2017

Application17/443,779Continuation

Application15/801,341Division

Application15/599,685Continuation

Application15/342,629Division

US 11,098,106 B2Related patent